Long-Term Testosterone Therapy in LOH with ED (Yassin et al., J Sex Med 2014)

Study Overview

• Original Research article from The Journal of Sexual Medicine (2014); long-term TU in LOH with ED.
• Population: men with late-onset hypogonadism (LOH) and erectile dysfunction (ED).
• Design: prospective, observational, longitudinal registry.
• Sample: $n=261$; mean age $\bar{A}=59.5 \pm 8.4$ years.
• Intervention: long-acting TU administered intramuscularly with dosing schedule of $1000\mathrm{mg}$ TU at day 1, at week 6, and every $3\mathrm{months}$ thereafter.
• Objectives: assess long-term and sustained effects on obesity/MetS parameters, health-related quality of life (HRQoL), and safety.

Aims

• Determine whether long-term TU produces sustained improvements in metabolic syndrome (MetS) parameters in LOH with ED.
• Evaluate impact on health-related quality of life.
• Assess safety of long-term TU therapy.

Methods

• Population: $n=261$ men with LOH and ED.
• Intervention: long-acting TU (intramuscular injections).
• Dosing: $1000\mathrm{mg}$ TU at day 1, at week 6, and every $3\mathrm{months}$ thereafter.
• Outcome measures (MetS-associated): obesity parameters (weight, waist circumference, BMI), lipid profile (total cholesterol, LDL, HDL, triglycerides), glucose, HbA1c, blood pressure; plus total testosterone and HRQoL.
• Duration: up to $5\text{-year}$ follow-up.

Outcome Measures (Main)

• Obesity: weight, waist circumference, BMI.
• Lipids: total cholesterol, LDL, HDL, triglycerides.
• Glycemia: fasting glucose, HbA1c.
• Vitals: blood pressure.
• Hormone: total testosterone.
• HRQoL: health-related quality of life.

Results

• Obesity parameters improved significantly over the $5\text{-year}$ study: reductions in body weight, waist circumference, and BMI.
• Lipid profile improved: decreases in total cholesterol, LDL, triglycerides; HDL increased.
• Glycemic control improved: fasting glucose and HbA1c decreased.
• Blood pressure decreased.
• Erectile function showed sustained improvement; muscle and joint pain reduced.
• HRQoL improved; there was a relationship between HRQoL and waist circumference.
• Safety: no evidence that long-term TU increases risk of prostate cancer.

Conclusions

• Long-term TU in men with LOH and ED reduces obesity parameters and improves metabolic syndrome and health-related quality of life.
• TU appears safe over the $5\text{-year}$ observation period with respect to prostate cancer risk.

Key Points

• Longitudinal TU use can yield sustained metabolic and QoL benefits in LOH with ED.
• Monitoring of obesity metrics, lipids, glucose, BP, and testosterone is essential.
• Safety assessment indicates no detected increase in prostate cancer risk over $5\text{-year}$ follow-up.